Fractionation gives therapeutic benefit in animal model of [177Lu]Lu-PSMA-617 therapy of prostate cancer [0.03%]
分馏治疗在[177Lu]Lu-PSMA-617治疗前列腺癌动物模型中的疗效优势
Oskar Vilhelmsson Timmermand,Axel Östholm,Wahed Zedan et al.
Oskar Vilhelmsson Timmermand et al.
Background: The clinical standard practice of [177Lu]Lu-PSMA-617 therapy is a single injection per treatment cycle, with 6 weeks between cycles. While clinical schedules currently utilize single-bolus cycles, splitting a ...
Correction: Differentiation and correlation of regional uptake heterogeneity with cardiac dysfunction in biopsy-proven transthyretin amyloid cardiomyopathy using quantitative single-photon emission computed tomography/computed tomography: a single-center, cross-sectional study [0.03%]
校正：使用定量单光子发射计算机断层成像/计算机断层扫描方法研究心脏功能障碍与组织活检证实的转甲状腺素蛋白淀粉样心肌病区域摄取异质性差异和相关性的单一中心横断面研究
Masakazu Tsujimoto,Hideki Kawai,Shingo Tanahashi et al.
Masakazu Tsujimoto et al.
Published Erratum
EJNMMI research. 2026 Mar 19;16(1):44. DOI:10.1186/s13550-026-01371-6 2026
Comparative evaluation of [¹⁸F]FAPI-42 and [¹⁸F]PSMA-1007 PET/CT for lesion detection and uptake in prostate cancer across disease stages [0.03%]
[18F]FAPI-42和[18F]PSMA-1007 PET/CT在前列腺癌不同分期中病灶检出及摄取的比较研究
Xingyu Mu,Meng Li,Jie Qin et al.
Xingyu Mu et al.
Background: Although [¹⁸F]PSMA-1007 enables sensitive detection in prostate cancer, heterogeneity in PSMA expression and variable physiologic uptake can limit performance, whereas [¹⁸F]FAPI-42, targeting fibroblast ac...
Outcome and safety of single-dose docetaxel-augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience [0.03%]
关于[¹⁷⁷Lu]Lu-PSMA-617放射配体治疗联合单剂多西他赛治疗难治性mCRPC的疗效和安全性：一项初步经验的证据
Niklas Ebert,Florian Rosar,Caroline Burgard et al.
Niklas Ebert et al.
Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting [0.03%]
前列腺癌的细胞表面肿瘤胎儿抗原：治疗潜力和放射配体靶向作用
Emirhan Harbi,Gokce Belge Bilgin,Louise Emmett et al.
Emirhan Harbi et al.
Comparison between [68Ga]Ga-FAPI-46 and [18F]FDG PET/CT uptake in luminal-like vs. HER2-positive breast cancer [0.03%]
[68Ga]Ga-FAPI-46和[18F]FDG PET/CT在类似腔隙型与HER2阳性乳腺癌中的摄取比较
Alina Toni Küper,Sofia Carrilho Vaz,Kim Magaly Pabst et al.
Alina Toni Küper et al.
Background: Fibroblast activation protein (FAP)-targeted tracers have emerged as promising agents for breast cancer imaging, with recent studies demonstrating PET performance comparable to or surpassing, that of [18F]FDG....
Optimal acquisition time of [68Ga]Ga-PentixaFor PET/CT for initial staging of multiple myeloma: an ancillary study to the PentiMyelo protocol [0.03%]
[68Ga]Ga-PentixaFor PET/CT初诊多发性骨髓瘤分期的 optimal 获取时间：PentiMyelo方案的探索性研究
Chloé François,Thomas Carlier,Cyrille Touzeau et al.
Chloé François et al.
A robust and versatile deep learning model for prediction of the arterial input function in dynamic small animal [18F] FDG PET imaging [0.03%]
一种稳健且通用的深度学习模型 用于小动物正电子发射断层成像中动脉输入函数的预测
Christian Salomonsen,Luigi T Luppino,Fredrik Aspheim et al.
Christian Salomonsen et al.
EJNMMI research: a vision for the next era of nuclear medicine [0.03%]
分子影像和核医学研究：展望下一个时代的影响学和核医学研究期刊
Marcus Hacker
Marcus Hacker
Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancer [0.03%]
interim ¹¹C-choline PET/CT预测阳性对镭-223治疗转移性去势抵抗性前列腺癌的反应价值
Eman E Ahmed,Jack R Andrews,Mohamed E Ahmed et al.
Eman E Ahmed et al.